Could a pill shrink nerve tumors in NF1? new trial aims to find out
NCT ID NCT04750928
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 6 times
Summary
This study tests the drug abemaciclib, typically used for cancer, in people with neurofibromatosis type 1 (NF1) who have atypical neurofibromas that cannot be surgically removed. The goal is to find a safe dose and see if it can shrink or stabilize these tumors. Participants take the drug twice daily for up to two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- abemaciclib
- What this could lead to
- If it works, this could provide a non-surgical treatment option for atypical neurofibromas in people with NF1.
- What could go wrong
- This is an early-phase trial with only 55 participants, so results may not apply to everyone. The drug may cause side effects and may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL NEUROFIBROMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo stop nerve tumors from turning cancerous?
- Light-Activated cream could slow growth of NF1 skin tumors
- Antioxidant drug shows promise for kids with NF1
- New drug combo shows promise for rare nerve tumors
- Could a common supplement help kids with NF1 learn and move better?
- New drug combo aims to tame rare childhood leukemia